Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying

As the Dow Jones index took a slight dip by over 50 points at the market’s close on Monday, insider actions within companies often serve as a litmus test of faith or skepticism in a company’s future. For observers interested in penny stocks, these insider dealings can paint a vivid backdrop to consider when making investment decisions.

Let’s delve into a few recent noteworthy insider transactions in the realm of penny stocks. For a more extensive overview, be sure to peruse Benzinga’s insider transactions platform.

A Shrewd Acquisition by AmeriServ Financial

• The Deal: AmeriServ Financial, Inc. ASRV Director Richard W. Bloomingdale scooped up a total of 1,783 shares at an average price of $2.85, amounting to an investment of approximately $5,086.
• Recent Developments: On Jan. 23, AmeriServ Financial reported a loss for the fourth quarter.
• AmeriServ Financial’s Focus: AmeriServ Financial Inc is a bank holding company primarily earning revenue from banking, bank-related services, and trust-related services.

Dakota Gold Digs Deeper

• The Purchase: Dakota Gold Corp. DC Director Alice D. Schroeder secured 7,410 shares at an average price of $1.96, expending around $14,521.
• Recent Events: On Feb. 21, Dakota Gold unveiled additional results for twelve drill holes from the Richmond Hill Gold Project.
• Dakota Gold’s Mission: Dakota Gold Corp is a gold exploration and development company with a keen focus on revitalizing the Homestake District in Lead, South Dakota, boasting high-quality gold mineral properties across over 40 thousand acres around the historic Homestake Mine.

Don’t Miss: Macy’s, Lowe’s and 3 Stocks to Keep an Eye on Heading into Tuesday

Galera Therapeutics Gains Momentum

• The Deal: Galera Therapeutics, Inc. GRTX 10% owner Yair Schneid obtained 932,402 shares at an average price of $0.18, investing around $166,417 into the company.
• Recent Advances: On Nov. 14, Galera Therapeutics reported a narrower-than-expected loss in the third quarter.
• Galera Therapeutics’ Focus: Galera Therapeutics Inc is a biopharmaceutical entity dedicated to developing and bringing to market an array of novel, proprietary therapeutics poised to revolutionize cancer radiotherapy.